NEW content
for 2015
Pfizer is delighted to announce that
the next Masterclass event will take
place on 24–25 April 2015 at the
Marriott Park Hotel, Rome.
This meeting is part of an enduring
programme for multidisciplinary
healthcare professionals involved
in Stroke Prevention in Non-Valvular
Atrial Fibrillation (NVAF).
Leading Excellence for Stroke Prevention
in Non-Valvular Atrial Fibrillation
24 – 25 April 2015 at the
Marriott Park Hotel, Rome
During this two-day meeting, we will review current
practice and unmet needs, explore the practical use of
Novel Oral Anticoagulants (NOACs) including their use in
various populations and consider their future alongside
existing treatment options.
By attending this meeting, you will:
•Understand the characteristics of NOACs, apixaban
in particular, explore their evolving use and discuss
how these may be integrated into the standard of care
•Hear about real world, practical information and
patient experience, as well as clinical data, patient
case studies and expert opinions
•Benefit from multidisciplinary, expert and peer-to-peer
learning, including exchange of best practice to
enhance patient care and clinical outcomes
This medicinal product is subject to additional monitoring.
Healthcare professionals are asked to report any suspected
adverse reactions via the national reporting system.
EURAPIX0057 • February 2015
This promotional meeting is organised and funded by Pfizer
MASTERCLASS AGENDA: 24–25 April 2015, Rome
Day 1
Day 2
12.00
Lunch
09.00
13.00
Chair’s opening address
Eli Lev (Israel)
Plenary Session 3
Plenary Session 1
Opening address
Robert Hatala (Slovakia)
09.15–09.35
13.15–13.40
Stroke prevention in NVAF patients: challenges in clinical practice
Juan Cosin (Spain)
Dose selection: the critical step in the development of NOACs
Anthony Porcari (Global, Pfizer)
09.35–09.55
13.40–14.05
Addressing the unmet needs: are all NOACs the same?
Robert Hatala (Slovakia)
Patient adherence? Think twice!
Bernard Vrijens (Belgium)
09.55–10.15
14.05–14.30
Recent advances in the treatment of VTE: the role of NOACs
Giancarlo Agnelli (Italy)
How to implement AF patient care
Deirdre Lane (UK)
10.15–10.30
Panel discussion /Q&A
14.30–14.45
Panel discussion/Q&A
10.30
Interactive case-based sessions (to include coffee break)
14.45
Interactive case-based sessions (to include coffee break)
Practical use of NOACs (EHRA* guidance)
•How to manage a patient with NVAF and coincident mild mitral regurgitation
•How to manage a patient with NVAF and concomitant coronary disease
Practical use of NOACs (EHRA* guidance)
•How to initiate a NOAC after a patient with NVAF has had a stroke
• How to manage stroke prevention in a frail NVAF patient
Content coordinated by Hans-Christoph Diener (Germany)
Content coordinated by Hein Heidbüchel (Belgium)
12.00
Lunch
Plenary Session 2
Plenary Session 4
16.10–16.35
Minimising the burden of anticoagulation-related bleeding
Menno Huisman (Netherlands)
13.00–13.15
Workshop summaries
TBC
16.35–17.00
Management of antithrombotic therapy in NVAF patients with
ACS/undergoing PCI
Eli Lev (Israel)
13.15–13.40
How to manage challenging patient case studies:
the multidisciplinary perspective
Daniel Pella (Slovakia)
17.00–17.15
Looking forward: clinical research with
Anthony Chan (Ireland, Pfizer)
13.40–14.05
The future of stroke prevention in NVAF: NOACs for all?
Giancarlo Agnelli (Italy)
17.15–17.30
Panel discussion/Q&A
14.05–14.30
Panel discussion/Q&A
17.30
Closing remarks
Eli Lev (Israel)
14.30
Closing remarks
Robert Hatala (Slovakia)
apixaban
This meeting will be conducted in English
*EHRA – European Heart Rhythm Association
STEERING COMMITTEE
•Stefan H Hohnloser, Chair
Professor of Medicine and Cardiology
and Director, Division of Clinical Electrophysiology,
J.W. Goethe University,
Frankfurt, Germany
• Hans-Christoph Diener
Professor
of Neurology,
University of Duisburg-Essen,
Germany
This promotional meeting is organised and funded by Pfizer
EURAPIX0057 • February 2015
• John Eikelboom
Associate
Professor,
Department of Medicine,
McMaster University,
Canada
• Hein Heidbüchel
Professor of Cardiology and
Arrhythmology,
Hasselt University and Heart Center,
Belgium
• Giancarlo Agnelli
Professor
of Internal Medicine,
University of Perugia,
Italy
This medicinal product is subject to additional monitoring. Healthcare professionals
are asked to report any suspected adverse reactions via the national reporting system.